Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Kythera Biopharmecuticals |
---|---|
Information provided by: | Kythera Biopharmecuticals |
ClinicalTrials.gov Identifier: | NCT00618618 |
Phase 2 trial to evaluate the safety and potential efficacy of one concentration of ATX-101, given in two dosing paradigms, compared to placebo for the reduction of submental fat.
Condition | Intervention | Phase |
---|---|---|
Reduction of Submental Fat |
Drug: Placebo vehicle Drug: ATX-101 1.0% concentration Drug: ATX-101 1.0% Concentration |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase, 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Given by Three Dosing Paradigms for the Reduction of Localized Subcutaneous Fat in the Submental Area |
Estimated Enrollment: | 60 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | January 2009 |
Estimated Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo: Placebo Comparator
Placebo vehicle
|
Drug: Placebo vehicle
Injection into submental fat q4w
|
2: ATX-101 1.0%: Active Comparator |
Drug: ATX-101 1.0% concentration
Injection into submental fat q4w
|
3: ATX-101 1.0%: Active Comparator |
Drug: ATX-101 1.0% Concentration
Injection into submental fat q4w
|
4: ATX-101 1.0%: Active Comparator |
Drug: ATX-101 1.0% Concentration
Injection into submental fat q4w
|
Ages Eligible for Study: | 25 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Australia | |
Sydney, Australia | |
Canada | |
Toronto, Canada | |
United Kingdom | |
Manchester, United Kingdom |
Study Director: | Patricia Walker, M.D., Ph.D. | Kythera Biopharmaceuticals, Inc. |
Responsible Party: | Kythera Biopharmaceuticals, Inc. ( Patricia Walker, M.D., Ph.D. ) |
Study ID Numbers: | ATX-101-07-07 |
Study First Received: | February 8, 2008 |
Last Updated: | July 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00618618 |
Health Authority: | Australia: National Health and Medical Research Council; United Kingdom: Medicines and Healthcare Products Regulatory Agency; Canada: Health Canada |
Deoxycholic Acid |
Therapeutic Uses Cholagogues and Choleretics Gastrointestinal Agents Pharmacologic Actions |